Neuro-Cells® is a clinical stage autologous stem cell treatment that aims to reduce irreversible impact and injury to the nerve system. The current clinical trials focus on Traumatic Spinal Cord Injury (TSCI). Next to this, Neuroplast aspires to make the technology available to other primarily inflammation-driven neurological disorders.
Neuro-Cells® is a disruptive clinical stage product with broad potential:
-
Autologous (patient and donor are the same person)
-
Available for acute treatment owing to GMP certified proprietary production technology
-
European Orphan Disease Designation (ODD) that enables fast-track development
-
Proven safety, tolerability and absence of product-related adverse effects for Traumatic Spinal Cord Injury after Phase I study
-
Existing preclinical evidence for other trauma-based neurological disorders
Neuro-Cells® is registered and patented.